Clinical Trials

36 enrolled

Bile Duct Neoplasms

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

280 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT07325539 2026-05-22

LIGHT

55 enrolled

Nasopharyngeal Carcinoma

NCT07603856 2026-05-22

REVIVE

39 enrolled

DermatologicGenitourinarySarcoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03093909 2026-05-20

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

44 enrolled

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT07598318 2026-05-20

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

Phase 2/3 Not yet recruiting

164 enrolled

Cholangiocarcinoma

NCT07599995 2026-05-20

GENE

34 enrolled

Biliary Tract Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

800 enrolled

Biliary Tract Neoplasms

NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

61 enrolled

Phase EARLY_PHASE1 Enrolling by invitation

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT00210041 2026-05-15

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Phase 1/2 Active not recruiting

50 enrolled

Genital Neoplasms, Male

NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

31 enrolled

Sarcoma

Osteosarcoma

NCT06591650 2026-05-14

GCND

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Phase 1/2 Not yet recruiting

12 enrolled

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03017326 2026-05-13

PHITT

450 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular, Hepatoblastoma

NCT01972919 2026-05-12

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

23 enrolled 8 charts

Pancreatic Neoplasms

NCT03415854 2026-05-12

NABPLAGEMD

34 enrolled 11 charts

Adenocarcinoma, Pancreatic Neoplasms

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06929286 2026-05-11

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06632327 2026-05-08

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT07466238 2026-05-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Phase NA Recruiting

40 enrolled

Phase 2/3 Active not recruiting

Biliary Tract Neoplasms

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05415917 2026-05-07

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Phase 2 Withdrawn

Phase 2 Active not recruiting

Pancreatic Neoplasms

NCT05524168 2026-05-07

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Nasopharyngeal Carcinoma

NCT03652428 2026-05-06

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

24 enrolled

Locally Advanced Pancreatic Cancer

NCT06023862 2026-05-06

DOVE

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06822010 2026-05-06

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

28 enrolled

Urinary Bladder Neoplasms

NCT07569679 2026-05-06

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

124 enrolled

Biliary Tract Neoplasms

NCT07570849 2026-05-06

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

35 enrolled

Cholangiocarcinoma

NCT04807816 2026-05-05

TARSARC

58 enrolled

Sarcoma

Leiomyosarcoma, Neoplasm Metastasis, Sarcoma

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Withdrawn

Phase 2 Active not recruiting

Borderline Resectable Pancreatic Adenocarcinoma

NCT06015659 2026-05-04

ZN-c3 + Gemcitabine in Pancreatic Cancer

12 enrolled

Pancreatic Neoplasms

NCT06958328 2026-05-04

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07529483 2026-04-30

ERASE-Chemo

35 enrolled

Phase 1 Active not recruiting

Pancreatic Cystic Neoplasm

NCT02495896 2026-04-29

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

61 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT00883480 2026-04-28

SLAT

Phase NA Completed

153 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Non-Small-Cell Lung

NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Terminated

6 enrolled 3 charts

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

34 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07420439 2026-04-27

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07365306 2026-04-24

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00885066 2026-04-23

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 1 Completed

30 enrolled

Pancreatic Neoplasms

NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Lymphoid

Hodgkin Disease

NCT06483555 2026-04-23

PANGEA

DermatologicGastrointestinal

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

40 enrolled 22 charts

Resectable Pancreatic Cancer

NCT04891289 2026-04-22

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

164 enrolled